AstraZeneca PLC (AZN)vsPro-Dex Inc (PDEX)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
PDEX
Pro-Dex Inc
$50.14
+0.60%
HEALTHCARE · Cap: $165.14M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 81368% more annual revenue ($58.74B vs $72.10M). AZN leads profitability with a 17.4% profit margin vs 15.7%. PDEX trades at a lower P/E of 15.1x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
PDEX
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
-30.5%
Fair Value
$29.14
Current Price
$50.14
$21.00 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Every $100 of equity generates 31 in profit
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : PDEX
The strongest argument for PDEX centers on Return on Equity, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 15.7% and operating margin at 17.5%. Revenue growth of 11.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : PDEX
The primary concerns for PDEX are Market Cap.
Key Dynamics to Monitor
AZN profiles as a value stock while PDEX is a mature play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.28 — expect wider price swings.
PDEX is growing revenue faster at 11.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 53/100), backed by strong 17.4% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Pro-Dex Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company is headquartered in Irvine, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?